Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
0.44 (1y: -81%)
Market Cap 41.8 M P/E(ttm)
Enterprise Value P/B 1.00
DCTH- NAS (USA)
Delcath Systems, Inc.
Not Rated
Top Ranked Predictable Companies
$0.44
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt No Debt
DCTH's Cash to Debt is ranked higher than
67% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.36 vs. DCTH: No Debt )
DCTH' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt
Equity to Asset 0.657
DCTH's Equity to Asset is ranked higher than
71% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.52 vs. DCTH: 0.657 )
DCTH' s 10-Year Equity to Asset Range
Min: 0.61   Max: 0.71
Current: 0.66
0.61
0.71
Interest Coverage -10000
DCTH's Interest Coverage is ranked lower than
119% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10000.00 vs. DCTH: -10000 )
DCTH' s 10-Year Interest Coverage Range
Min: -10000   Max: -10000
Current: -10000
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -15569.70
DCTH's Operating margin (%) is ranked lower than
117% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.70 vs. DCTH: -15569.70 )
DCTH' s 10-Year Operating margin (%) Range
Min: -15569.7   Max: -15569.7
Current: -15569.7
Net-margin (%) -14990.8
DCTH's Net-margin (%) is ranked lower than
110% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. DCTH: -14990.8 )
DCTH' s 10-Year Net-margin (%) Range
Min: -14990.8   Max: -14990.8
Current: -14990.8
ROE (%) -259.2
DCTH's ROE (%) is ranked lower than
92% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. DCTH: -259.2 )
DCTH' s 10-Year ROE (%) Range
Min: -259.2   Max: -259.2
Current: -259.2
ROA (%) -170.2
DCTH's ROA (%) is ranked lower than
96% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. DCTH: -170.2 )
DCTH' s 10-Year ROA (%) Range
Min: -170.2   Max: -170.2
Current: -170.2
ยป DCTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q1 2012

DCTH Guru Trades in Q1 2012

Jim Simons Sold Out
» More
Q2 2012

DCTH Guru Trades in Q2 2012

Jim Simons 391,362 sh (New)
» More
Q3 2012

DCTH Guru Trades in Q3 2012

Jim Simons 140,247 sh (-64.16%)
» More
Q4 2012

DCTH Guru Trades in Q4 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DCTH

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2011-03-31 Sold Out $6.18 - $11.44 $ 0.44-95%0
George Soros 2010-09-30 New Buy$5.53 - $8.69 $ 0.44-94%19600
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 1.00
DCTH's P/B is ranked lower than
78% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. DCTH: 1.00 )
DCTH' s 10-Year P/B Range
Min: 0   Max: 7.1
Current: 1
0
7.1
P/S 42.80
DCTH's P/S is ranked lower than
118% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. DCTH: 42.80 )
DCTH' s 10-Year P/S Range
Min: 0   Max: 776.2
Current: 42.8
0
776.2
EV-to-EBIT 76.9
DCTH's EV-to-EBIT is ranked higher than
90% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.70 vs. DCTH: 76.9 )
DCTH' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 76.9

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 2.2
DCTH's Price/Net Cash is ranked higher than
82% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.70 vs. DCTH: 2.2 )
DCTH' s 10-Year Price/Net Cash Range
Min: 0   Max: 0
Current: 2.2
Price/Net Current Asset Value 2.3
DCTH's Price/Net Current Asset Value is ranked higher than
79% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. DCTH: 2.3 )
DCTH' s 10-Year Price/Net Current Asset Value Range
Min: 0   Max: 0
Current: 2.3
Price/Tangible Book 1.5
DCTH's Price/Tangible Book is ranked higher than
60% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. DCTH: 1.5 )
DCTH' s 10-Year Price/Tangible Book Range
Min: 0   Max: 0
Current: 1.5

Business Description

Delcath Systems, Inc. is a Delaware corporation incorporated in August 1988. The Company is a development stage, specialty pharmaceutical and medical device company focused on oncology, initially cancers in the liver. Since its inception, it has directed its research efforts towards the development and clinical study of the Delcath chemosaturation system. The Company currently operates in one business segment, which is the development and commercialization of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers high doses of chemotherapeutic agents directly to the liver, while limiting systemic exposure and the related side effects by filtering the blood prior to returning it to the patient. The Delcath chemosaturation system involves a series of three catheter insertions, each of which is placed percutaneously through standard interventional radiology techniques. The procedure is minimally invasive and repeatable allowing for multiple courses of treatment with chemotherapeutic drugs and the potential for concomitant cancer therapies. The Company assembles, sterilizes and packages the Delcath chemosaturation system at its facility in Queensbury, New York and has established its European headquarters and distribution facility in Galway, Ireland. Delcath currently utilizes contract manufacturers to manufacture some components of the Delcath chemosaturation system. The Delcath chemosaturation system competes with all forms of liver cancer treatments. The Delcath chemosaturation system is subject to extensive and rigorous government regulation by foreign regulatory agencies and the FDA.
Company Website
SEC Reports
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:DV3.Germany
ยป More Articles for DCTH

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
Delcath Systems Inc. Reports Operating Results (10-Q) Oct 23 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial